Subsequent Events

3 Months Ended

Mar. 31, 2023

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

Positive Decision in Litigation Matters

On April 10, 2023, the presiding judge in the federal securities class action, Neurelis, Inc. v. Aquestive Therapeutics, Inc., filed in the United States Court for the District of New Jersey, ordered the dismissal of the class action with prejudice pursuant to a Stipulation of Voluntary Dismissal filed by the parties in that action. On April 21, 2023, the same presiding judge ordered the dismissal with prejudice of a related shareholder derivative lawsuit, Loreen Niewenhuis v. Keith Kendall, et al, pursuant to a Stipulation of Voluntary Dismissal filed by the parties in that action. Refer to Note 19, Contingencies for details.

Nasdaq's Listing Rule 5450(a)(1) Compliance

On April 13, 2023, the Company received a notice from Nasdaq” informing the Company that it has regained compliance with Nasdaq's Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market, as the minimum bid price of the Company’s Common Stock had met or exceeded $1.00 per share for a minimum of ten consecutive business days during the applicable 180-day review period.